Supernus Pharma (SUPN) Tops Q4 EPS by 5c, Revenues Miss; Offers FY21 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 28.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.15 | 52 Week High | $26.84 | |||
| Open | $28.15 | 52 Week Low | $9.51 | |||
| Day High | $28.15 | P/E | N/A | |||
| Day Low | $28.15 | EPS | $-2.62 | |||
| Volume | 5,153 | |||||
